ABSTRACT

Stroke is a disease that occurs when the inventory of blood to the brain is either blocked or ruptured. At the point when this occurs, the cerebrum fails to get enough oxygen or supplements, that leads to the death of the brain cells.It is one of the main source for causing high mortality and disability. It has been characterized either as Ischemic stroke or Haemorrhagic stroke. The most common risk factors are Hypertension, Atrial fibrillation, Heart failure, smoking, liquor utilization, over weight and hypercholesterolemia. Different pharmacological agents are used for the treatment of stroke either through intruding on the sub-atomic pathways prompting neuronal death or improving neuronal endurance and recovery. Apart from recombinant tissue plasminogen activator (rtPA), there are few agents that could treat the stroke, have been prevailing in clinical testing. Early revascularization is as of now the most settled treatment for acute ischemic stroke that adequately improves clinical results. The current research in the medical field is focusing on creating the neuroprotective agents for stroke treatment, and novel sub-atomic focuses for neuroprotection and neuro restoration and this has been found to anticipate the clinical advantages. In this review the risk factors, basic pharmacological treatments and clinical manifestation for ischemic stroke are discussed. Keywords: Brain, Stroke, Haemorrhage, Ischemia, Tissue Plasminogen Activator Pharmacological agents, Neuroprotection
Publication date: 01/10/2020

https://ijbpas.com/pdf/2020/October/MS_IJBPAS_2020_5212.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.10.5212